title: Cholecalciferol 20 000 IU Once Weekly in HIV-Positive Patients with Low Vitamin D Levels: Result from a Cohort Study.
abstract: To evaluate efficacy and safety of 20 000 IU cholecalciferol weekly in HIV-infected patients.
  
  
  
  Longitudinal data for 243 HIV-infected patients with paired 25-OH-vitamin D3 values for the same month in 2 consecutive years were stratified by the initiation of supplementation in this retrospective study.
  
  
  
  After 1 year of administration of cholecalciferol 20 000 IU weekly, about 78% of patients with initial vitamin D level <20 µg/L achieved vitamin D levels >20 µg/L and 42% achieved levels >30 µg/L. Supplemented patients with baseline vitamin D levels <20 µg/L showed a significant risk reduction for hypocalcemia ( P = .006; risk difference: 20.8%) and a significantly lower increase in alkaline phosphatase (AP) compared to those in the nonsubstituted group.
  
  
  
  The dose of 20 000 IU of cholecalciferol once weekly was found to be safe and effective. Normalization of vitamin D levels within 1 year was observed in 42% to 75% of the patients.
authors.affiliation: 1 MVZ Karlsplatz, HIV Clinical Care and Research Center, Munich, Germany.
authors.forename: Sebastian
authors.identifier: 0000-0001-6863-3275
authors.initials: S
authors.lastname: Noe
authors.affiliation: 1 MVZ Karlsplatz, HIV Clinical Care and Research Center, Munich, Germany.
authors.forename: Silke
authors.initials: S
authors.lastname: Heldwein
authors.affiliation: 1 MVZ Karlsplatz, HIV Clinical Care and Research Center, Munich, Germany.
authors.forename: Rita
authors.initials: R
authors.lastname: Pascucchi
authors.affiliation: 1 MVZ Karlsplatz, HIV Clinical Care and Research Center, Munich, Germany.
authors.forename: Celia
authors.initials: C
authors.lastname: Oldenbüttel
authors.affiliation: 1 MVZ Karlsplatz, HIV Clinical Care and Research Center, Munich, Germany.
authors.forename: C
authors.initials: C
authors.lastname: Wiese
authors.affiliation: 1 MVZ Karlsplatz, HIV Clinical Care and Research Center, Munich, Germany.
authors.forename: Ariane
authors.initials: A
authors.lastname: von Krosigk
authors.affiliation: 1 MVZ Karlsplatz, HIV Clinical Care and Research Center, Munich, Germany.
authors.forename: Eva
authors.initials: E
authors.lastname: Jägel-Guedes
authors.affiliation: 1 MVZ Karlsplatz, HIV Clinical Care and Research Center, Munich, Germany.
authors.forename: Hans
authors.initials: H
authors.lastname: Jäger
authors.affiliation: 2 MVZ Bavariahaus, Munich, Germany.
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Mayer
authors.affiliation: 1 MVZ Karlsplatz, HIV Clinical Care and Research Center, Munich, Germany.|3 Department of Medicine II, University Hospital Klinikum rechts der Isar, Munich, Germany.|4 German Center for Infection Research (DZIF), Braunschweig, Germany.|5 MUC Research, Munich, Germany.
authors.forename: Christoph D
authors.identifier: 0000-0002-3875-5367
authors.initials: CD
authors.lastname: Spinner
authors.affiliation: 5 MUC Research, Munich, Germany.
authors.forename: Eva
authors.initials: E
authors.lastname: Wolf
mesh_terms: D000328:Adult; D000469:Alkaline Phosphatase / Q000097:blood; D002118:Calcium / Q000097:blood; D002762:Cholecalciferol / Q000008:administration & dosage*; D005260:Female; D006679:HIV Seropositivity / Q000150:complications*; D006801:Humans; D006996:Hypocalcemia / Q000209:etiology; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D014807:Vitamin D / Q000097:blood*; D014808:Vitamin D Deficiency / Q000150:complications / Q000188:drug therapy*; D014815:Vitamins / Q000008:administration & dosage*
chemical_list: D014815:Vitamins; D014807:Vitamin D; D002762:Cholecalciferol; D000469:Alkaline Phosphatase; D002118:Calcium
keywords: HIV; cholecalciferol; supplementation; weekly